Literature DB >> 33606974

Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis.

Radha Mukherjee1, Kiran G Vanaja2, Jacob A Boyer1, Sunyana Gadal1, Hilla Solomon1, Sarat Chandarlapaty3, Andre Levchenko4, Neal Rosen5.   

Abstract

The PI3K pathway regulates cell metabolism, proliferation, and migration, and its dysregulation is common in cancer. We now show that both physiologic and oncogenic activation of PI3K signaling increase the expression of its negative regulator PTEN. This limits the duration of the signal and output of the pathway. Physiologic and pharmacologic inhibition of the pathway reduces PTEN and contributes to the rebound in pathway activity in tumors treated with PI3K inhibitors and limits their efficacy. Regulation of PTEN is due to mTOR/4E-BP1-dependent control of its translation and is lost when 4E-BP1 is deleted. Translational regulation of PTEN is therefore a major homeostatic regulator of physiologic PI3K signaling and plays a role in reducing the pathway activation by oncogenic PIK3CA mutants and the antitumor activity of PI3K pathway inhibitors. However, pathway output is hyperactivated in tumor cells with coexistent PI3K mutation and loss of PTEN function.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4E-BP; BYL-719; PI3K signaling; PTEN regulation; PTEN translation; computational model of PI3K signaling; growth factor signaling; mTOR; negative feedback; resistance to PI3K inhibition

Mesh:

Substances:

Year:  2021        PMID: 33606974      PMCID: PMC8384339          DOI: 10.1016/j.molcel.2021.01.033

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  57 in total

1.  Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.

Authors:  Cullen M Taniguchi; Thien T Tran; Tatsuya Kondo; Ji Luo; Kohjiro Ueki; Lewis C Cantley; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

Review 2.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

3.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Authors:  Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

Authors:  Peggy P Hsu; Seong A Kang; Jonathan Rameseder; Yi Zhang; Kathleen A Ottina; Daniel Lim; Timothy R Peterson; Yongmun Choi; Nathanael S Gray; Michael B Yaffe; Jarrod A Marto; David M Sabatini
Journal:  Science       Date:  2011-06-10       Impact factor: 47.728

5.  YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29.

Authors:  Karen Tumaneng; Karin Schlegelmilch; Ryan C Russell; Dean Yimlamai; Harihar Basnet; Navin Mahadevan; Julien Fitamant; Nabeel Bardeesy; Fernando D Camargo; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2012-12       Impact factor: 28.824

6.  Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Authors:  Sarit Schwartz; John Wongvipat; Cath B Trigwell; Urs Hancox; Brett S Carver; Vanessa Rodrik-Outmezguine; Marie Will; Paige Yellen; Elisa de Stanchina; José Baselga; Howard I Scher; Simon T Barry; Charles L Sawyers; Sarat Chandarlapaty; Neal Rosen
Journal:  Cancer Cell       Date:  2014-12-24       Impact factor: 31.743

Review 7.  Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.

Authors:  Enrique Rozengurt; Heloisa P Soares; James Sinnet-Smith
Journal:  Mol Cancer Ther       Date:  2014-10-16       Impact factor: 6.261

Review 8.  A complex interplay between Akt, TSC2 and the two mTOR complexes.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem Soc Trans       Date:  2009-02       Impact factor: 5.407

9.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

10.  Metabolic labeling with noncanonical amino acids and visualization by chemoselective fluorescent tagging.

Authors:  Susanne Tom Dieck; Anke Müller; Anne Nehring; Flora I Hinz; Ina Bartnik; Erin M Schuman; Daniela C Dieterich
Journal:  Curr Protoc Cell Biol       Date:  2012-09
View more
  9 in total

1.  AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

Authors:  Shanade Dunn; Cath Eberlein; Jason Yu; Albert Gris-Oliver; Swee Hoe Ong; Urs Yelland; Natalie Cureton; Anna Staniszewska; Robert McEwen; Millie Fox; James Pilling; Philip Hopcroft; Elizabeth A Coker; Patricia Jaaks; Mathew J Garnett; Beverley Isherwood; Violeta Serra; Barry R Davies; Simon T Barry; James T Lynch; Kosuke Yusa
Journal:  Oncogene       Date:  2022-10-14       Impact factor: 8.756

2.  Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?

Authors:  Panagiota Efstathia Nikolaou; Nikolaos Mylonas; Manousos Makridakis; Marina Makrecka-Kuka; Aikaterini Iliou; Stelios Zerikiotis; Panagiotis Efentakis; Stavros Kampoukos; Nikolaos Kostomitsopoulos; Reinis Vilskersts; Ignatios Ikonomidis; Vaia Lambadiari; Coert J Zuurbier; Agnieszka Latosinska; Antonia Vlahou; George Dimitriadis; Efstathios K Iliodromitis; Ioanna Andreadou
Journal:  Basic Res Cardiol       Date:  2022-05-17       Impact factor: 12.416

Review 3.  The role of non-coding RNAs in myocarditis: a narrative review.

Authors:  Wenhu Liu; Jing Hu; Shuai Lu; Zhaohui Wang
Journal:  Ann Transl Med       Date:  2022-09

Review 4.  Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity.

Authors:  Sarah Christine Elisabeth Wright; Natali Vasilevski; Violeta Serra; Jordi Rodon; Pieter Johan Adam Eichhorn
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 5.  Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics.

Authors:  Sophia G Kisling; Gopalakrishnan Natarajan; Ramesh Pothuraju; Ashu Shah; Surinder K Batra; Sukhwinder Kaur
Journal:  Cancer Metastasis Rev       Date:  2021-09-30       Impact factor: 9.264

6.  PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation.

Authors:  Yi Na Yoon; Eunju Lee; Young-Ju Kwon; Jeong-An Gim; Tae-Jin Kim; Jae-Sung Kim
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

7.  The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.

Authors:  Yanan Liu; Juanjuan Feng; Kun Yuan; Zhengzhen Wu; Longmiao Hu; Yue Lu; Kun Li; Jiawei Guo; Jing Chen; Chengbin Ma; Xiufeng Pang
Journal:  Elife       Date:  2022-05-03       Impact factor: 8.140

8.  CDC42 governs normal oviduct multiciliogenesis through activating AKT to ensure timely embryo transport.

Authors:  Ruiwei Jiang; Xiaofang Tang; Jiale Pan; Gaizhen Li; Ningjie Yang; Yedong Tang; Shilei Bi; Han Cai; Qionghua Chen; Dunjin Chen; Haibin Wang; Shuangbo Kong
Journal:  Cell Death Dis       Date:  2022-09-02       Impact factor: 9.685

9.  A systematic analysis of signaling reactivation and drug resistance.

Authors:  Boris N Kholodenko; Nora Rauch; Walter Kolch; Oleksii S Rukhlenko
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.